Has the U.K. Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 20.1x which is lower than its 3-year average PE of 25.6x. The industry is trading close to its 3-year average PS ratio of 3.4x.

How does U.K. Pharma compare with similar industries?

There are no additional sub-industries under this industry.

U.K. (FTSE) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 10 May 2026	UK£315.7b	UK£91.3b	UK£15.7b	17.6x	20.1x	3.5x
Tue, 07 Apr 2026	UK£362.2b	UK£91.4b	UK£15.7b	20x	23x	4x
Thu, 05 Mar 2026	UK£358.1b	UK£90.8b	UK£15.7b	21.6x	22.9x	3.9x
Sat, 31 Jan 2026	UK£325.6b	UK£88.5b	UK£14.5b	23.7x	22.5x	3.7x
Mon, 29 Dec 2025	UK£323.1b	UK£89.2b	UK£14.6b	21.8x	22.2x	3.6x
Wed, 26 Nov 2025	UK£329.9b	UK£90.4b	UK£14.8b	21.9x	22.3x	3.6x
Fri, 24 Oct 2025	UK£297.5b	UK£88.1b	UK£11.8b	20.6x	25.3x	3.4x
Sun, 21 Sep 2025	UK£271.9b	UK£87.6b	UK£11.7b	18.7x	23.2x	3.1x
Tue, 19 Aug 2025	UK£278.7b	UK£87.5b	UK£11.7b	21.7x	23.8x	3.2x
Thu, 17 Jul 2025	UK£258.5b	UK£86.7b	UK£10.7b	25.8x	24.3x	3x
Sat, 14 Jun 2025	UK£274.4b	UK£86.2b	UK£10.6b	27.2x	25.9x	3.2x
Mon, 12 May 2025	UK£258.4b	UK£87.2b	UK£10.7b	26.3x	24.2x	3x
Wed, 09 Apr 2025	UK£255.1b	UK£88.2b	UK£9.8b	29.2x	26x	2.9x
Fri, 07 Mar 2025	UK£291.4b	UK£87.9b	UK£9.6b	29.1x	30.3x	3.3x
Sun, 02 Feb 2025	UK£241.2b	UK£75.9b	UK£7.8b	33.6x	30.7x	3.2x
Tue, 31 Dec 2024	UK£223.1b	UK£75.5b	UK£7.8b	31.1x	28.6x	3x
Thu, 28 Nov 2024	UK£225.8b	UK£75.0b	UK£7.7b	31.9x	29.2x	3x
Sat, 26 Oct 2024	UK£247.0b	UK£72.5b	UK£9.1b	29.9x	27.2x	3.4x
Mon, 23 Sep 2024	UK£252.7b	UK£71.5b	UK£8.9b	37.8x	28.3x	3.5x
Wed, 21 Aug 2024	UK£275.9b	UK£72.3b	UK£9.0b	41.1x	30.6x	3.8x
Fri, 19 Jul 2024	UK£258.0b	UK£70.8b	UK£9.5b	35.5x	27.3x	3.6x
Sun, 16 Jun 2024	UK£267.2b	UK£71.6b	UK£9.6b	31.5x	27.9x	3.7x
Tue, 14 May 2024	UK£273.1b	UK£72.0b	UK£9.6b	37.2x	28.4x	3.8x
Thu, 11 Apr 2024	UK£242.0b	UK£71.1b	UK£9.7b	32.5x	24.8x	3.4x
Sat, 09 Mar 2024	UK£235.2b	UK£70.1b	UK£9.7b	31x	24.3x	3.4x
Mon, 05 Feb 2024	UK£237.0b	UK£69.8b	UK£9.5b	35.2x	24.8x	3.4x
Wed, 03 Jan 2024	UK£239.1b	UK£69.1b	UK£10.7b	35.8x	22.3x	3.5x
Fri, 01 Dec 2023	UK£226.1b	UK£69.1b	UK£10.7b	33.6x	21.1x	3.3x
Sun, 29 Oct 2023	UK£229.1b	UK£70.8b	UK£10.4b	54x	22.1x	3.2x
Tue, 26 Sep 2023	UK£250.4b	UK£70.6b	UK£10.4b	55.8x	24.2x	3.5x
Thu, 24 Aug 2023	UK£236.5b	UK£69.0b	UK£10.2b	53.5x	23.3x	3.4x
Sat, 22 Jul 2023	UK£237.3b	UK£67.4b	UK£7.8b	52x	30.3x	3.5x
Mon, 19 Jun 2023	UK£251.8b	UK£67.4b	UK£7.9b	55.5x	32x	3.7x
Wed, 17 May 2023	UK£259.8b	UK£68.4b	UK£8.0b	57.3x	32.6x	3.8x


GB Market	-0.81%
Healthcare	-1.92%
Pharma	-1.87%
Pharma	-1.87%

Company	Last Price	7D	1Y	Valuation
AGY Allergy Therapeutics	UK£0.11	5.9% +UK£38.0m	52.8%	PS12x
HIK Hikma Pharmaceuticals	UK£14.18	0.7% +UK£20.4m	-29.3%	PE10.3x
EAH ECO Animal Health Group	UK£0.97	3.7% +UK£2.4m	55.2%	PE21.8x
NFX Nuformix	UK£0.0021	20.6% +UK£913.4k	57.7%	PB7.1x
POLB Poolbeg Pharma	UK£0.043	1.2% +UK£352.6k	55.4%	PB3.6x

Announcement • May 06

ImmuPharma PLC Initiates IND-Enabling Program for Kapiglucagon to Treat Diabetes

ImmuPharma PLC initiated IND-enabling activities for its Kapiglucagon diabetes program, following the execution of a 'Work Order' with specialist pharmaceutical consultancy tranScrip Limited. Under the agreement, tranScrip will support the development of the regulatory strategy and the preparation and execution of a pre-IND meeting with the FDA, including the preparation of an integrated briefing package and IND planning activities. The program is expected to progress through a streamlined development pathway, with ImmuPharma evaluating a 505(b)(2) regulatory approach in the United States, leveraging existing data on native glucagon, subject to FDA confirmation. Kapiglucagon is a proprietary glucagon prodrug being developed for the treatment of Type 1 diabetes (T1D), to overcome the inherent physicochemical limitations of native glucagon. The program is designed to improve solubility and formulation stability, with potential application in dual-hormone artificial pancreas systems and other glucagon-based therapeutic settings, which are expected to support the development of next-generation alternatives to current insulin-only pump devices. The global Insulin Pump market is forecast to reach $13.6 billion sales by 2035. ImmuPharma has previously stated that it has an accelerated development plan for Kapiglucagon, through a 505(b)(2) regulatory pathway and that the program is being supported by the recently approved funding initiative, which is intended to advance the asset over the next two years. Kapiglucagon has established a strong scientific rationale and a growing body of supporting manufacturing and preclinical data, which the Company believes provides a solid foundation for further development. A key milestone in the IND-enabling process will be a pre-IND meeting with the FDA to align on the regulatory pathway and the scope of the required Chemistry, Manufacturing and Controls (CMC), preclinical and clinical program. Following this meeting, ImmuPharma intends to progress towards IND submission and, subject to regulatory alignment, first-in-human studies to support the next stage of value creation for Kapiglucagon. Kapiglucagon has been developed to address the key pharmaceutical limitations associated with native glucagon. It is a water-soluble glucagon prodrug designed to maintain high stability in aqueous solution while regenerating native glucagon in vivo following subcutaneous administration. Unlike native glucagon, which rapidly aggregates and forms fibrils in solution, Kapiglucagon demonstrates excellent solubility and formulation stability, enabling the development of clean, saline-based formulations that do not clog pump-based delivery systems. This improved physicochemical profile makes Kapiglucagon particularly well suited for continuous or intermittent delivery in advanced diabetes technologies, including next-generation artificial pancreas systems. By combining the therapeutic activity of native glucagon with a formulation that overcomes its inherent instability, Kapiglucagon has the potential to provide more reliable and practical dual-hormone automated glucose control solutions for patients with Type 1 Diabetes and avoid the long-term health complications of inadequate blood glucose control. ImmuPharma's vision is to position Kapiglucagon as a key enabling solution for next-generation artificial pancreas technologies. By overcoming the long-standing instability of native glucagon in aqueous formulations, Kapiglucagon offers the potential to deliver a stable, pump-compatible glucagon source, allowing dual-hormone closed-loop systems to operate safely and effectively. A 505(b)(2) is a U.S. FDA drug approval pathway that sits between a full NDA and a generic. The 505(b)(2) approval route allows a company to obtain approval for a modified version of an existing drug by relying partly on data which the FDA already has for the reference product, in this case a glucagon brand. The timeframe, cost and clinical study requirements for completing such a program may be considerably reduced compared to a normal NDA (new drug application) that follows a full 505(b)(1) NDA development pathway. A (PTE) Patent Term Extension of 5 years may also be applied to the existing patent life of Kapiglucagon which could result in a patent expiry extension to 2043. Kapiglucagon has established a strong scientific rationale and a growing body of supporting CMC and preclinical data, which the Company believes provides a solid foundation for further development. The first step is expected to be a Pre-IND meeting with the FDA to align on the proposed regulatory pathway and the scope of the required CMC, preclinical and clinical program. Following this interaction, the Company intends to advance the remaining development activities, including IND-enabling work, with the objective of entering a focused clinical study designed to generate safety, pharmacokinetic and pharmacodynamic data to support the next stage of value creation for Kapiglucagon.

U.K. (FTSE) Pharma Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Poolbeg Pharma PLC, Annual General Meeting, Jun 09, 2026

New minor risk - Market cap size

ImmuPharma PLC Initiates IND-Enabling Program for Kapiglucagon to Treat Diabetes

Centrum Launches Newly Reformulated Adults 50+ Complete Multivitamin with Clinically Shown Cognitive Benefits

AstraZeneca Eyes $80b Ambition With Rising Oncology Sales and Mixed FDA Drug Decisions

GSK Halts Alzheimer’s Trial Buys 35Pharma and Gains UK Approval for Lynavoy

HIK: Buyback Plan And Index Shift Will Support Future Re Rating

New major risk - Share price stability

New minor risk - Financial data availability

Eco Animal Health Group plc Announces Appointment of Andrew Winder as Head of Business Development, Effective May 11, 2026

First half 2026 earnings released: UK£0.004 loss per share (vs UK£0.002 loss in 1H 2025)

New major risk - Shareholder dilution

New major risk - Financial position